Career
- Home
- Career
About DR Sanjai K Addla
Hi I Am Dr. Sanjai
Consultant Uro-oncological surgeon / Robotic Surgeon Apollo Cancer Institute, Jubilee Hills, Hyderabad
We take great pleasure in informing you that Dr Sanjai Addla has joined the Apollo family as Consultant surgical urology-oncologist / Robotic surgery in the Oncology department of Apollo Hospitals, Jubilee Hills, Hyderabad.
Dr Sanjai Addla has spent the last 18 years in the United Kingdom where he strongly imbibed the UK medical culture. Following General Surgical training and MRCS (2000), he was trained in urology, FRCS (Urology) 2007. He then underwent specialist uro-oncology and robotic surgical training at The Christie hospital (largest cancer treatment centre in Europe) and fellowship in Brussels. He has been a consultant urological surgeon at Bradford teaching hospital with expertise in cancer and robotic surgery since 2009.
Dr Sanjai Addla specializes in providing surgical treatment for cancers of prostate, kidney and bladder. He has extensive experience in robotic surgery with more than 4 year experience as a consultant in robotic surgery.
He has performed more than 250 robotic prostatectomies and more than 150 robotic partial nephrectomies. The excellent surgical outcomes from his robotic surgical teamhave been presented and published robotic experience as well as results from other clinical research have been presented at various national and international conferences. He was involved in setting up the North of England Robotic Urological Surgeons (NERUS) group to further collaboration between the twelve robotic centres in the North of England. He organised the annual meeting of the NERUS in Bradford for two consecutive years.
He was awarded a higher research degree (MD) from University of Manchester for undertaking research on stem cell origin of renal cell cancer.
He introduced robotic surgery in Bradford and has extended his role to lead the Uro-oncology team and was also the lead cancer clinician overseeing the delivery of cancer care across all cancer sites.
